N-alkyl-N-[2-hydroxy-3-(aryloxy)propanyl]-2-(arylsulfonyl)benzylamine and preparation method and application

Abstract

The invention discloses the structure of N-alkyl-N-[2-hydroxyl-3-(aryloxy) propalkyl]-2-(arylthioyl) benzylamine with anti-depression activity, its preparing process and use, wherein the preparing process comprises reacting 1 mol of aryl phenol with 1-10 mol of epioxychloropropane in 1-5 mol aqueous solution of potassium carbonate or sodium carbonate at the presence of tetra butyl ammonium bromide for 12-48 hours under room temperature, thus obtaining 3-aryloxy epioxypropane, then subjecting 1 mol of N-alkyl-2-(arylthioyl) benzylamine and 1-5 mol of 3-aryloxy epioxypropane to backflow reaction for 5-48 hours in anhydrous alcohol or absolute methanol. The compounds can be in existence by the form of free alkali or salt for preparing medicaments for resisting depression. The advantages of the invention include simple preparing process and easy operation.

Description

technical field [0001] The present invention relates to a structure of N-alkyl-N-[2-hydroxyl-3-(aryloxy)propanyl]-2-(arylthio)benzylamine with antidepressant activity, its preparation method and application , the technology belongs to the field of medicinal chemistry. Background technique [0002] Depression is a common mental illness, which is an emotional disorder. As the pace of life continues to accelerate, people's mental pressure is gradually increasing. Depression has become a common disease in modern society, with a high incidence, and its incidence is rising rapidly. : According to incomplete statistics, at present the world's depression patients have accounted for 3%-5% of the world's population, almost seen in all ages, and its prevalence is about 3% in the general population, and the patient population in general hospital health services In patients with chronic physical diseases (such as cardiovascular disease, diabetes), the rate of depressive disorder can be ...

AI Technical Summary

Problems solved by technology

[0003] Tricyclic antidepressants (TCA, Anticholinergic) appeared in the 1950s, and 5-HT selective reuptake inhibitors SSRIs (Fluoxetine, Paroxetine, Sertaline, Citalopram, Fluvoxamine) appeared in the 1980s because of their good antidepressant properties, It has gradually replaced TCA and has become the leading product in the antidepressant market. However, because SSRI indirectly acts on all 5-HT receptors, it has side effects such as nausea, anxiety, insomnia, and sexual dysfunction. The weakness is the hysteresis effect, that is, the antidepressant effect usually appears after the first 2-6 weeks after starting to take the medicine. Therefore, in order to find antidepressants that are safe, fast-acting, and have few side effects, pharmacists have conducted various researches. try

[0004] Since the 1990s, some antidepressants with new mechanisms of action have appeared, such as NE / 5-HT reuptake inhibitor SNRI (Venlaxine, Milnacipran, Duloxetine, Nefazodone), selective monoamine oxidase inhibitor MAOI (Moclobe mide, Toloxatone), selective NE Reuptake inhibitor NARI (Reboxetine), NE energy and specific 5-HT energy antidepressant NaSSa (Mirtazapine), although these drugs have improved efficacy and rapid onset compared with SSRIs, but there are still 1 -2-week lag period, so research on faster-acting drugs is urgent

Images